Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Sep 22

PMID 31540435

Citations 5

Authors

Bilikis Aderonke Abolarinwa

Ridwan Babatunde Ibrahim

Yen-Hua Huang

Affiliations

Soon will be listed here.

Abstract

Gastrointestinal (GI) cancer is one of the common causes of cancer-related death worldwide. Chemotherapy and/or immunotherapy are the current treatments, but some patients do not derive clinical benefits. Recently, studies from cancer molecular subtyping have revealed that tumor molecular biomarkers may predict the immunotherapeutic response of GI cancer patients. However, the therapeutic response of patients selected by the predictive biomarkers is suboptimal. The tumor immune-microenvironment apparently plays a key role in modulating these molecular-determinant predictive biomarkers. Therefore, an understanding of the development and recent advances in immunotherapeutic pharmacological intervention targeting tumor immune-microenvironments and their potential predictive biomarkers will be helpful to strengthen patient immunotherapeutic efficacy. The current review focuses on an understanding of how the host-microenvironment interactions and the predictive biomarkers can determine the efficacy of immune checkpoint inhibitors. The contribution of environmental pathogens and host immunity to GI cancer is summarized. A discussion regarding the clinical evidence of predictive biomarkers for clinical trial therapy design, current immunotherapeutic strategies, and the outcomes to GI cancer patients are highlighted. An understanding of the underlying mechanism can predict the immunotherapeutic efficacy and facilitate the future development of personalized therapeutic strategies targeting GI cancers.

Citing Articles

A Rare Case of Large-Cell Neuroendocrine Carcinoma Metastasizing to the Brain: A Case Report.

Mohamed Y, Salih A, Suliman O, Hamad I, Hussein A Cureus. 2024; 16(10):e70615.

PMID: 39483593 PMC: 11526616. DOI: 10.7759/cureus.70615.

Unravelling the role of intratumoral bacteria in digestive system cancers: current insights and future perspectives.

Lu W, Aihaiti A, Abudukeranmu P, Liu Y, Gao H J Transl Med. 2024; 22(1):545.

PMID: 38849871 PMC: 11157735. DOI: 10.1186/s12967-024-05320-6.

Colitis-associated carcinogenesis: crosstalk between tumors, immune cells and gut microbiota.

Li J, Ji Y, Chen N, Dai L, Deng H Cell Biosci. 2023; 13(1):194.

PMID: 37875976 PMC: 10594787. DOI: 10.1186/s13578-023-01139-8.

IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment.

Liu K, Huang A, Nie J, Tan J, Xing S, Qu Y Front Immunol. 2021; 12:683332.

PMID: 34093586 PMC: 8176033. DOI: 10.3389/fimmu.2021.683332.

Transcriptome Based System Biology Exploration Reveals Homogeneous Tumorigenicity of Alimentary Tract Malignancy.

Lu Y, Shi J, Zhang Z, Zhou J, Zhou H, Feng Y Front Oncol. 2021; 10:580276.

PMID: 33552958 PMC: 7862768. DOI: 10.3389/fonc.2020.580276.

References

Martinez M, Moon E . CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol. 2019; 10:128. PMC: 6370640. DOI: 10.3389/fimmu.2019.00128. View

Angka L, Martel A, Kilgour M, Jeong A, Sadiq M, de Souza C . Natural Killer Cell IFNγ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery. Ann Surg Oncol. 2018; 25(12):3747-3754. DOI: 10.1245/s10434-018-6691-3. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Katlinski K, Gui J, Katlinskaya Y, Ortiz A, Chakraborty R, Bhattacharya S . Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell. 2017; 31(2):194-207. PMC: 5313042. DOI: 10.1016/j.ccell.2017.01.004. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Mellman I, Hubbard-Lucey V, Tontonoz M, Kalos M, Chen D, Allison J . De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunol Res. 2016; 4(4):279-88. DOI: 10.1158/2326-6066.CIR-16-0045. View

Della Chiesa M, Pesce S, Muccio L, Carlomagno S, Sivori S, Moretta A . Features of Memory-Like and PD-1(+) Human NK Cell Subsets. Front Immunol. 2016; 7:351. PMC: 5021715. DOI: 10.3389/fimmu.2016.00351. View

Hagland H, Lea D, Watson M, Soreide K . Correlation of Blood T-Cells to Intratumoural Density and Location of CD3 and CD8 T-Cells in Colorectal Cancer. Anticancer Res. 2017; 37(2):675-683. DOI: 10.21873/anticanres.11363. View

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

10.

Taylor N, Vick S, Iglesia M, Brickey W, Midkiff B, McKinnon K . Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. J Clin Invest. 2017; 127(9):3472-3483. PMC: 5669567. DOI: 10.1172/JCI90499. View

11.

Fan Y, Mao R, Yang J . NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 2013; 4(3):176-85. PMC: 4875500. DOI: 10.1007/s13238-013-2084-3. View

12.

Blatner N, Mulcahy M, Dennis K, Scholtens D, Bentrem D, Phillips J . Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med. 2012; 4(164):164ra159. PMC: 3762575. DOI: 10.1126/scitranslmed.3004566. View

13.

Wang Y, Sedimbi S, Lofbom L, Singh A, Porcelli S, Cardell S . Unique invariant natural killer T cells promote intestinal polyps by suppressing TH1 immunity and promoting regulatory T cells. Mucosal Immunol. 2017; 11(1):131-143. PMC: 5638666. DOI: 10.1038/mi.2017.34. View

14.

Wang S, Hong S, Wezeman M, Qian J, Yang J, Yi Q . Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma. Front Biosci. 2007; 12:3566-75. DOI: 10.2741/2335. View

15.

Whiteside T . The role of regulatory T cells in cancer immunology. Immunotargets Ther. 2016; 4:159-71. PMC: 4918255. DOI: 10.2147/ITT.S55415. View

16.

Hazama S, Tamada K, Yamaguchi Y, Kawakami Y, Nagano H . Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Ann Gastroenterol Surg. 2018; 2(4):289-303. PMC: 6036392. DOI: 10.1002/ags3.12180. View

17.

Pushalkar S, Hundeyin M, Daley D, Zambirinis C, Kurz E, Mishra A . The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 2018; 8(4):403-416. PMC: 6225783. DOI: 10.1158/2159-8290.CD-17-1134. View

18.

Steele C, Karim S, Leach J, Bailey P, Upstill-Goddard R, Rishi L . CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2016; 29(6):832-845. PMC: 4912354. DOI: 10.1016/j.ccell.2016.04.014. View

19.

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

20.

Charych D, Hoch U, Langowski J, Lee S, Addepalli M, Kirk P . NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models. Clin Cancer Res. 2016; 22(3):680-90. DOI: 10.1158/1078-0432.CCR-15-1631. View